Tau-Targeting vs Monoclonal Antibody — Neurology Deal Terms Comparison
Market Analysis
In neurology, Tau-Targeting and Monoclonal Antibody represent two of the most actively transacted modalities. At Phase 2, Tau-Targeting deals carry a median total deal value of $4.1B with $464M upfront, compared to $3.1B total value and $354M upfront for Monoclonal Antibody. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Tau-Targeting development milestones average $1.2B versus $916M for Monoclonal Antibody. Commercial milestones are $1.1B for Tau-Targeting and $861M for Monoclonal Antibody. Royalty rates range from 13.5%-21.6% for Tau-Targeting and 12.5%-20% for Monoclonal Antibody.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Tau-Targeting and Monoclonal Antibody deal terms compare in neurology?
Which modality commands higher royalty rates: Tau-Targeting or Monoclonal Antibody?
How do milestone structures differ between Tau-Targeting and Monoclonal Antibody?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.